Skip to content
stoqly
en Β· USD

Appearance

Language

Currency

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 26, 2026.

Sign in

Phibro Animal Health Corp

PAHC Nasdaq Pharmaceutical Preparations Financials FY2017–FY2026

Phibro Animal Health Corp had $1.5B of revenue in fiscal 2026, up 17.1% on the year before. Over five years, revenue changed +12.7% a year on average.

Last close Β· Oct 23, 2026

$38.80

2.5%

What Phibro Animal Health Corp does

PAHC Β· Pharmaceutical Preparations

From its latest annual report

No business description yet.

Filing details

Legal name
PHIBRO ANIMAL HEALTH CORP
Fiscal year ends
June 30, 2026
Latest annual report
10-K Β· Aug 26, 2026
Accession Β· CIK
0001104659-26-101493 Β· 0001069899

Earnings calendar Β· Phibro Animal Health Corp

Every quarter, companies publish how much they sold and earned. These are the days Phibro Animal Health Corp did it, and the next one. Share prices often move a lot on those days.

Next results

November 4, 2026

Wednesday Β· in 9 days

Time
Time not announced
Covers
Period ended Sep 30, 2026
Expected EPS
$0.79
Source
Earnings calendar
See who else reports that week β†’
Date Results for Time Source
Aug 26, 2026 Q4 '26 After the market closes 8-K β†—
May 6, 2026 Q3 '26 After the market closes 8-K β†—
Feb 4, 2026 Q2 '26 After the market closes 8-K β†—
Nov 4, 2025 Q1 '26 Time not announced 8-K β†—
Aug 27, 2025 Q4 '25 After the market closes 8-K β†—
May 7, 2025 Q3 '25 After the market closes 8-K β†—
Feb 5, 2025 Q2 '25 After the market closes 8-K β†—
Nov 5, 2024 Q1 '25 Time not announced 8-K β†—

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

KIRA’s summary AI analyst

Hi! I read Phibro Animal Health Corp’s latest annual report (fiscal 2026). Here is what stands out:

4 strengths

1.Sales and profit

See section β†’
  • Phibro Animal Health Corp had $1.5B of revenue in fiscal 2026, up 17.1% on the year before. Over five years, revenue changed +12.7% a year on average.
  • Its operating margin was 12.8%, up 4.3Β pts: of every 100 in sales, about 13 is left after running the business.
  • Phibro Animal Health Corp made $99.7M of net profit in fiscal 2026. From fiscal 2017 to 2026, diluted EPS grew 4.7% a year.

2.Cash and shareholders

See section β†’
  • Free cash flow was $9.9M in fiscal 2026, 0.6% of revenue.
  • Phibro Animal Health Corp returned $19.5M to shareholders in fiscal 2026, 197% of free cash flow. The diluted share count rose 0.7%.
  • In the last 12 months, insiders bought $0.3M and sold $28.6M of shares on the open market.

Phibro Animal Health Corp in 30 seconds

Good So-so Weak

Good

Are sales growing?

+17.1%

Yes. Sales grew 17.1% last year.

So-so

Does it make a profit?

6.6%

A little. It keeps 6.6% of every sale as profit.

So-so

Does profit turn into cash?

0.6%

Partly. 0.6% of sales ends up as free cash.

So-so

How healthy are the accounts?

6 / 8

Mixed. It passes 6 of 8 health tests.

For information

How is the share priced?

16.0x

One share costs 16.0 times its yearly profit per share.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2026

Market cap Last close times the latest diluted share count, so it is approximate.
$1.6B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
16.0x
On $2.43 EPS (TTM)

Revenue

Total sales reported in the income statement.

KIRA Β· Phibro Animal Health Corp had $1.5B of revenue in fiscal 2026, up 17.1% on the year before. Over five years, revenue changed +12.7% a year on average.

See the full section β†’

Operating margin

Operating income as a share of revenue.

KIRA Β· Its operating margin was 12.8%, up 4.3Β pts: of every 100 in sales, about 13 is left after running the business.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· Phibro Animal Health Corp made $99.7M of net profit in fiscal 2026. From fiscal 2017 to 2026, diluted EPS grew 4.7% a year.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

KIRA Β· Free cash flow was $9.9M in fiscal 2026, 0.6% of revenue.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Sales and profit

Is it selling more, and how much does it keep?

Revenue and margins

KIRA Β· Phibro Animal Health Corp had $1.5B of revenue in fiscal 2026, up 17.1% on the year before. Over five years, revenue changed +12.7% a year on average. Its operating margin was 12.8%, up 4.3Β pts: of every 100 in sales, about 13 is left after running the business.

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Revenue

Revenue

Margins, % of revenue

Gross Operating Net FCF

Margins, % of revenue

Gross Operating Net FCF

Net income and earnings per share

KIRA Β· Phibro Animal Health Corp made $99.7M of net profit in fiscal 2026. From fiscal 2017 to 2026, diluted EPS grew 4.7% a year.

Loss periods are shown in red.

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Net income

Net income

Diluted EPS

Diluted EPS

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

KIRA Β· Free cash flow was $9.9M in fiscal 2026, 0.6% of revenue.

Cash from operations minus capital spending.

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Free cash flow

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Cash from operations vs capital spending

Cash from operations Capital spending

Dividends, buybacks and share count

KIRA Β· Phibro Animal Health Corp returned $19.5M to shareholders in fiscal 2026, 197% of free cash flow. The diluted share count rose 0.7%.

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Dividends and buybacks

Dividends Buybacks

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

Insider trades

KIRA Β· In the last 12 months, insiders bought $0.3M and sold $28.6M of shares on the open market.

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Bought, 12 months

$0.3M

1 insider

Sold, 12 months

$28.6M

2 insiders

Of sales under plans

100%

$28.6M

DateInsiderTradeSharesPriceValueFiling
May 29, 2026 E Thomas CorcoranDirector Bought 10,000 $31.77 $0.3M Form 4
May 7, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 4,528 $48.49 $0.2M Form 4
May 6, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 7,040 $57.37 $0.4M Form 4
May 5, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 7,040 $55.80 $0.4M Form 4
Apr 30, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 7,040 $52.77 $0.4M Form 4
Apr 29, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 7,040 $52.92 $0.4M Form 4
Apr 28, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 7,040 $55.91 $0.4M Form 4
Apr 23, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 7,040 $54.10 $0.4M Form 4
Apr 22, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 7,040 $54.29 $0.4M Form 4
Apr 21, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 7,040 $55.98 $0.4M Form 4
Apr 16, 2026 BFI Co., LLC10% owner Sold plan 7,040 $54.64 $0.4M Form 4
Apr 15, 2026 BFI Co., LLC10% owner Sold plan 7,040 $56.96 $0.4M Form 4
Apr 14, 2026 BFI Co., LLC10% owner Sold plan 7,040 $59.08 $0.4M Form 4
Mar 31, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 7,040 $53.90 $0.4M Form 4
Mar 30, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 7,040 $53.61 $0.4M Form 4
Mar 26, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 7,040 $56.81 $0.4M Form 4
Mar 25, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 7,040 $55.91 $0.4M Form 4
Mar 24, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 7,040 $52.93 $0.4M Form 4
Mar 19, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 7,040 $52.52 $0.4M Form 4
Mar 18, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 10,560 $52.68 $0.6M Form 4
Mar 17, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 5,280 $51.66 $0.3M Form 4
Mar 13, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 5,280 $48.91 $0.3M Form 4
Feb 26, 2026 BFI Co., LLC10% owner Sold plan 7,040 $53.73 $0.4M Form 4
Feb 25, 2026 BFI Co., LLC10% owner Sold plan 7,040 $51.71 $0.4M Form 4
Feb 24, 2026 BFI Co., LLC10% owner Sold plan 7,040 $51.37 $0.4M Form 4
Feb 20, 2026 BFI Co., LLC10% owner Sold plan 7,040 $51.41 $0.4M Form 4
Feb 19, 2026 BFI Co., LLC10% owner Sold plan 7,040 $50.26 $0.4M Form 4
Feb 18, 2026 BFI Co., LLC10% owner Sold plan 7,040 $51.40 $0.4M Form 4
Feb 13, 2026 BFI Co., LLC10% owner Sold plan 7,040 $51.96 $0.4M Form 4
Feb 11, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 14,184 $51.62 $0.7M Form 4
Feb 10, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 58,014 $51.81 $3.0M Form 4
Feb 5, 2026 BFI Co., LLC10% owner Sold plan 110,842 $48.38 $5.4M Form 4
Feb 4, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 3,520 $41.15 $0.1M Form 4
Feb 3, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 9,660 $41.47 $0.4M Form 4
Jan 30, 2026 BFI Co., LLC10% owner Sold plan 6,693 $40.09 $0.3M Form 4
Jan 29, 2026 BFI Co., LLC10% owner Sold plan 6,772 $40.12 $0.3M Form 4
Jan 23, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 1,235 $40.55 $0.1M Form 4
Jan 22, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 13,158 $41.99 $0.6M Form 4
Jan 21, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 14,687 $41.68 $0.6M Form 4
Jan 15, 2026 BFI Co., LLC10% owner Sold plan 2,932 $40.02 $0.1M Form 4
Jan 14, 2026 BFI Co., LLC10% owner Sold plan 3,651 $40.53 $0.1M Form 4
Jan 13, 2026 BFI Co., LLC10% owner Sold plan 7,551 $40.32 $0.3M Form 4
Jan 9, 2026 BFI Co., LLC10% owner Sold plan 213 $40.16 $0.0M Form 4
Jan 7, 2026 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 328 $40.09 $0.0M Form 4
Dec 11, 2025 BFI Co., LLC10% owner Sold plan 5,752 $40.93 $0.2M Form 4
Dec 9, 2025 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 1,288 $40.19 $0.1M Form 4
Dec 8, 2025 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 3,520 $40.06 $0.1M Form 4
Dec 4, 2025 BFI Co., LLC10% owner Sold plan 3,520 $41.22 $0.1M Form 4
Dec 3, 2025 BFI Co., LLC10% owner Sold plan 3,520 $40.77 $0.1M Form 4
Dec 1, 2025 BFI Co., LLC10% owner Sold plan 3,520 $41.66 $0.1M Form 4
Nov 28, 2025 BFI Co., LLC10% owner Sold plan 3,520 $42.54 $0.1M Form 4
Nov 26, 2025 BFI Co., LLC10% owner Sold plan 5,280 $44.02 $0.2M Form 4
Nov 25, 2025 BFI Co., LLC10% owner Sold plan 7,040 $43.93 $0.3M Form 4
Nov 20, 2025 BFI Co., LLC10% owner Sold plan 3,520 $41.76 $0.1M Form 4
Nov 18, 2025 BFI Co., LLC10% owner Sold plan 5,280 $43.82 $0.2M Form 4
Nov 17, 2025 BFI Co., LLC10% owner Sold plan 5,280 $44.56 $0.2M Form 4
Nov 13, 2025 BFI Co., LLC10% owner Sold plan 8,801 $44.48 $0.4M Form 4
Nov 12, 2025 BFI Co., LLC10% owner Sold plan 21,536 $45.23 $1.0M Form 4
Nov 10, 2025 BFI Co., LLC10% owner Sold plan 38,303 $45.29 $1.7M Form 4
Nov 7, 2025 BFI Co., LLC10% owner Sold plan 3,520 $42.86 $0.2M Form 4
Nov 5, 2025 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 3,520 $41.21 $0.1M Form 4
Nov 4, 2025 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 3,520 $43.10 $0.2M Form 4
Oct 30, 2025 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 3,520 $41.07 $0.1M Form 4
Oct 29, 2025 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 3,520 $41.66 $0.1M Form 4
Oct 28, 2025 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 3,520 $41.56 $0.1M Form 4
Oct 24, 2025 BFI Co., LLC10% owner Sold plan 3,520 $41.75 $0.1M Form 4
Oct 23, 2025 BFI Co., LLC10% owner Sold plan 3,520 $40.18 $0.1M Form 4
Oct 22, 2025 BFI Co., LLC10% owner Sold plan 11,859 $40.27 $0.5M Form 4
Oct 20, 2025 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 16,075 $40.38 $0.6M Form 4
Oct 17, 2025 Jack BendheimPresident and CEO, Director, 10% owner Sold plan 700 $40.03 $0.0M Form 4
Sep 30, 2025 BFI Co., LLC10% owner Sold plan 20,664 $40.38 $0.8M Form 4

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

Cash, debt and the ratios that show how comfortably Phibro Animal Health Corp can carry it.

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments $91.2M$81.3M$115M$77.0M$82.0M
Debt incl. finance leases $288M$356M$312M$632Mβ€”
Net debt / EBITDA 1.8x2.6x2.2x3.6xβ€”
Debt / equity 1.1x1.3x1.2x2.2xβ€”
Interest coverage 6.2x3.8x2.3x3.0x4.2x
Current ratio 3.0x3.3x2.9x2.8x3.0x
Quick ratio 1.6x1.8x1.6x1.2x1.3x
Total assets $932M$971M$982M$1.4B$1.5B
Total liabilities $669M$689M$726M$1.1B$1.1B
Shareholders' equity $262M$283M$257M$286M$385M
Net debt (βˆ’ = net cash) $197M$275M$197M$555Mβ€”

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

Piotroski F-score

KIRA Β· Phibro Animal Health Corp passes 6 of 8 financial health tests (Piotroski F-score).

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

TestFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Net income is positive βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“
Cash from operations is positive βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“
Return on assets rose β€” βœ• βœ• βœ• βœ“ βœ• βœ• βœ• βœ“ βœ“
Cash from operations exceeds net income βœ“ βœ“ βœ• βœ“ βœ• βœ• βœ• βœ“ βœ“ βœ•
Debt fell relative to assets β€” βœ“ βœ“ βœ“ βœ• βœ“ βœ• βœ“ βœ• β€”
Current ratio rose β€” βœ• βœ“ βœ• βœ“ βœ• βœ“ βœ• βœ• βœ“
Share count didn't rise β€” βœ• βœ• βœ• βœ“ βœ“ βœ“ βœ• βœ• βœ•
Gross margin rose β€” βœ“ βœ• βœ“ βœ“ βœ• βœ“ βœ“ βœ“ βœ“
Revenue rose relative to assets β€” βœ• βœ• βœ• βœ• βœ“ βœ• βœ“ βœ• βœ“
F-score β€” / 35 / 94 / 95 / 96 / 95 / 95 / 96 / 95 / 96 / 8
Accruals ratio βˆ’5.4%βˆ’0.8%1.1%βˆ’3.4%0.7%2.0%2.0%βˆ’8.7%βˆ’2.7%2.1%
Altman Z'' 4.434.694.794.154.474.494.574.203.974.70

All figures

Every number, year by year.

10 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Download CSV
Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Revenue $764M $820M $828M $800M $833M $942M $978M $1.0B $1.3B $1.5B
Net interest income βˆ’$14.9M βˆ’$11.9M βˆ’$11.8M βˆ’$12.9M βˆ’$12.9M βˆ’$11.9M βˆ’$15.3M β€” β€” β€”
Gross profit $248M $267M $265M $257M $271M $285M $298M $313M $400M $513M
Research and development $9.4M $10.0M $12.1M $13.7M $17.8M $20.8M $24.4M $29.2M $23.7M $24.6M
Operating income $97.9M $98.9M $83.2M $69.2M $74.9M $79.0M $71.8M $53.3M $110M $194M
Interest expense $16.9M $13.6M $13.7M $14.6M $13.7M $12.7M $18.7M $23.0M $37.2M $46.4M
Pretax income $80.5M $88.1M $71.5M $55.5M $66.5M $72.3M $54.1M $10.9M $68.0M $137M
Income tax $15.9M $23.2M $16.8M $22.0M $12.1M $23.2M $21.5M $8.5M $19.7M $37.6M
Net income $64.6M $64.9M $54.7M $33.6M $54.4M $49.2M $32.6M $2.4M $48.3M $99.7M
Net income to common β€” β€” β€” $33.6M $54.4M $49.2M $32.6M $2.4M $48.3M $99.7M
Diluted EPS $1.61 $1.61 $1.35 $0.83 $1.34 $1.21 $0.81 $0.06 $1.19 $2.43
Diluted shares 0.00B 0.00B 0.00B 0.04B 0.04B 0.04B 0.04B 0.04B 0.04B 0.04B
Cash flow
Cash from operations $98.4M $70.0M $47.2M $59.3M $48.3M $31.6M $13.3M $87.6M $80.1M $69.0M
Capital expenditure $20.9M $18.5M $29.9M $34.0M $29.3M $37.0M $51.8M $41.2M $38.3M $59.1M
Free cash flow $77.5M $51.5M $17.3M $25.3M $19.0M βˆ’$5.4M βˆ’$38.5M $46.4M $41.8M $9.9M
Depreciation and amortization $26.0M $26.9M $27.6M $32.3M $31.9M $32.7M $34.0M $36.2M $45.6M $51.5M
Stock-based compensation $0.0M $0.3M $2.3M $2.3M $1.1M β€” β€” $0.5M $0.7M $1.6M
Acquisitions β€” β€” β€” β€” β€” $13.5M β€” $3.3M $287M β€”
Dividends paid $15.8M $16.1M $18.6M $19.4M $19.4M $19.4M $19.4M $19.4M $19.4M $19.5M
Dividends and buybacks $15.8M $16.1M $18.6M $19.4M $19.4M $19.4M $19.4M $19.4M $19.4M $19.5M
Balance sheet
Cash and short-term investments $56.1M $79.2M $81.6M $91.3M $93.2M $91.2M $81.3M $115M $77.0M $82.0M
Total debt $248M $242M $230M $237M $306M $288M $356M $312M $632M β€”
Current assets $364M $415M $466M $452M $499M $566M $586M $601M $811M $936M
Current liabilities $116M $143M $154M $157M $164M $191M $176M $204M $293M $316M
Inventory $161M $178M $198M $197M $216M $259M $278M $266M $444M $535M
Property and equipment, net $127M $130M $140M $148M $155M $165M $196M $203M $355M $369M
Goodwill $24.0M $27.3M $27.3M $52.7M $52.7M $53.2M $53.3M $54.6M $59.6M $60.0M
Intangible assets $54.6M $52.0M $47.5M $71.0M $62.3M $63.9M $55.0M $45.0M $36.5M $30.1M
Total assets $623M $672M $727M $784M $841M $932M $971M $982M $1.4B $1.5B
Total liabilities $472M $487M $511M $596M $603M $669M $689M $726M $1.1B $1.1B
Shareholders' equity $151M $185M $216M $188M $239M $262M $283M $257M $286M $385M
Margins
Gross margin 32.5% 32.5% 32.0% 32.1% 32.6% 30.3% 30.5% 30.8% 30.9% 33.8%
Operating margin 12.8% 12.1% 10.1% 8.6% 9.0% 8.4% 7.3% 5.2% 8.5% 12.8%
EBITDA margin 16.2% 15.4% 13.4% 12.7% 12.8% 11.9% 10.8% 8.8% 12.0% 16.2%
Net margin 8.5% 7.9% 6.6% 4.2% 6.5% 5.2% 3.3% 0.2% 3.7% 6.6%
FCF margin 10.1% 6.3% 2.1% 3.2% 2.3% βˆ’0.6% βˆ’3.9% 4.6% 3.2% 0.6%
Net interest share of revenue βˆ’2.0% βˆ’1.5% βˆ’1.4% βˆ’1.6% βˆ’1.5% βˆ’1.3% βˆ’1.6% β€” β€” β€”
Returns
Return on capital 22.9% 20.9% 17.5% 13.5% 13.6% 11.7% 8.4% 7.6% 9.3% β€”
Return on capital employed 19.3% 18.7% 14.5% 11.0% 11.1% 10.7% 9.0% 6.9% 10.3% 16.4%
Return on equity 42.7% 38.6% 27.3% 16.6% 25.5% 19.6% 12.0% 0.9% 17.8% 29.7%
Return on assets 10.4% 10.0% 7.8% 4.4% 6.7% 5.5% 3.4% 0.2% 4.1% 7.0%
Return on tangible equity 89.0% 61.4% 38.8% 52.0% 44.0% 33.8% 18.7% 1.5% 25.5% 33.8%
Growth
Revenue growth β€” 7.3% 1.0% βˆ’3.3% 4.1% 13.1% 3.8% 4.1% 27.4% 17.1%
Net income growth β€” 0.4% βˆ’15.7% βˆ’38.7% 62.1% βˆ’9.6% βˆ’33.7% βˆ’92.6% 1,897.7% 106.6%
EPS growth β€” 0.0% βˆ’16.1% βˆ’38.5% 61.4% βˆ’9.7% βˆ’33.1% βˆ’92.6% 1,883.3% 104.2%
FCF growth β€” βˆ’33.6% βˆ’66.4% 46.4% βˆ’25.0% βˆ’128.4% β€” β€” βˆ’9.8% βˆ’76.4%
Share count change β€” 1.0% 0.2% 99,909.9% 0.0% 0.0% 0.0% 0.0% 0.4% 0.7%
Financial health
Net debt / EBITDA 1.5x 1.3x 1.3x 1.4x 2.0x 1.8x 2.6x 2.2x 3.6x β€”
Debt / equity 1.6x 1.3x 1.1x 1.3x 1.3x 1.1x 1.3x 1.2x 2.2x β€”
Interest coverage 5.8x 7.3x 6.1x 4.7x 5.5x 6.2x 3.8x 2.3x 3.0x 4.2x
Current ratio 3.1x 2.9x 3.0x 2.9x 3.0x 3.0x 3.3x 2.9x 2.8x 3.0x
Quick ratio 1.7x 1.7x 1.7x 1.6x 1.7x 1.6x 1.8x 1.6x 1.2x 1.3x
Capital allocation
Capex / revenue 2.7% 2.3% 3.6% 4.3% 3.5% 3.9% 5.3% 4.1% 3.0% 3.9%
Stock comp / revenue 0.0% 0.0% 0.3% 0.3% 0.1% β€” β€” 0.0% 0.1% 0.1%
Payouts / FCF 20.4% 31.2% 107.6% 76.7% 102.3% β€” β€” 41.9% 46.5% 197.3%
Quality scores
Piotroski F-score β€” 5.0 4.0 5.0 6.0 5.0 5.0 6.0 5.0 6.0
Altman Z'' 4.4 4.7 4.8 4.2 4.5 4.5 4.6 4.2 4.0 4.7
Accruals ratio βˆ’5.4% βˆ’0.8% 1.1% βˆ’3.4% 0.7% 2.0% 2.0% βˆ’8.7% βˆ’2.7% 2.1%

Source: SEC EDGAR XBRL filings (CIK 0001069899). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open